Denali Therapeutics To Report Third Quarter 2026 Financial Results And Business Highlights On November 3, 2026
Denali's management will host a conference call and webcast on Tuesday, November 3, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss third quarter 2026 financial results and provide a general business update.
The live webcast, along with a slide presentation, may be accessed through the Investors section of Denali's website at or by clicking here. A replay of the webcast will be archived on Denali's website for a limited time following the call.
About Denali Therapeutics
Denali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier (BBB) using its proprietary TransportVehicleTM platform. With the first FDA-approved biologic specifically designed to cross the BBB, a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, Denali is advancing toward its goal of delivering effective medicines to transform life for people with neurodegenerative diseases, lysosomal storage disorders and other serious diseases. For more information, please visit .
Investor Contact:Laura Hansen
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment